Management of microscopic colitis: challenges and solutions

Julia Shor,1 Gustavo Churrango,1 Nooshin Hosseini,2 Christopher Marshall1 1Department of Gastroenterology, University of Massachusetts Medical School, Worcester, MA, USA; 2Department of Gastroenterology, Mount Sinai Hospital, New York, NY, USA Abstract: Microscopic colitis (MC) is a chronic inflamma...

Full description

Bibliographic Details
Main Authors: Shor J, Churrango G, Hosseini N, Marshall C
Format: Article
Language:English
Published: Dove Medical Press 2019-02-01
Series:Clinical and Experimental Gastroenterology
Subjects:
Online Access:https://www.dovepress.com/management-of-microscopic-colitis-challenges-and-solutions-peer-reviewed-article-CEG
id doaj-b621a1082a8842eaaefb261a670fc65d
record_format Article
spelling doaj-b621a1082a8842eaaefb261a670fc65d2020-11-25T02:27:41ZengDove Medical PressClinical and Experimental Gastroenterology1178-70232019-02-01Volume 1211112044358Management of microscopic colitis: challenges and solutionsShor JChurrango GHosseini NMarshall CJulia Shor,1 Gustavo Churrango,1 Nooshin Hosseini,2 Christopher Marshall1 1Department of Gastroenterology, University of Massachusetts Medical School, Worcester, MA, USA; 2Department of Gastroenterology, Mount Sinai Hospital, New York, NY, USA Abstract: Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by nonbloody diarrhea in the setting of normal appearing colonic mucosa. MC has two main subtypes based on histopathologic features, collagenous colitis and lymphocytic colitis. Management of both subtypes is the same, with treatment goal of reducing the number of bowel movements and improving consistency. First-line treatment involves counseling the patient about decreasing their risk factors, like discontinuing smoking and avoiding medications with suspected association such as NSAIDs, proton pump inhibitor, ranitidine, and sertraline. Starting loperamide for immediate symptomatic relief is used as an adjunct to therapy with glucocorticoids. Budesonide is considered first-line treatment for MC given its favorable side effect profile and good efficacy, though relapse rates are high. Systemic glucocorticoids should be reserved to patients unable to take budesonide. In glucocorticoid refractory disease, medications that have been tried include cholestyramine, bismuth salicylate, antibiotics, probiotics, aminosalicylates, immunomodulators, and anti-tumor necrosis factor-alpha inhibitors. More research is needed for the creation of a systematic stepwise approach for relapsing and refractory disease. Keywords: microscopic colitis, diarrhea, collagenous colitis, lymphocytic colitis, management, inflammatory colitis  https://www.dovepress.com/management-of-microscopic-colitis-challenges-and-solutions-peer-reviewed-article-CEGmicroscopic colitisdiarrheacollagenous colitislymphocytic colitismanagement
collection DOAJ
language English
format Article
sources DOAJ
author Shor J
Churrango G
Hosseini N
Marshall C
spellingShingle Shor J
Churrango G
Hosseini N
Marshall C
Management of microscopic colitis: challenges and solutions
Clinical and Experimental Gastroenterology
microscopic colitis
diarrhea
collagenous colitis
lymphocytic colitis
management
author_facet Shor J
Churrango G
Hosseini N
Marshall C
author_sort Shor J
title Management of microscopic colitis: challenges and solutions
title_short Management of microscopic colitis: challenges and solutions
title_full Management of microscopic colitis: challenges and solutions
title_fullStr Management of microscopic colitis: challenges and solutions
title_full_unstemmed Management of microscopic colitis: challenges and solutions
title_sort management of microscopic colitis: challenges and solutions
publisher Dove Medical Press
series Clinical and Experimental Gastroenterology
issn 1178-7023
publishDate 2019-02-01
description Julia Shor,1 Gustavo Churrango,1 Nooshin Hosseini,2 Christopher Marshall1 1Department of Gastroenterology, University of Massachusetts Medical School, Worcester, MA, USA; 2Department of Gastroenterology, Mount Sinai Hospital, New York, NY, USA Abstract: Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by nonbloody diarrhea in the setting of normal appearing colonic mucosa. MC has two main subtypes based on histopathologic features, collagenous colitis and lymphocytic colitis. Management of both subtypes is the same, with treatment goal of reducing the number of bowel movements and improving consistency. First-line treatment involves counseling the patient about decreasing their risk factors, like discontinuing smoking and avoiding medications with suspected association such as NSAIDs, proton pump inhibitor, ranitidine, and sertraline. Starting loperamide for immediate symptomatic relief is used as an adjunct to therapy with glucocorticoids. Budesonide is considered first-line treatment for MC given its favorable side effect profile and good efficacy, though relapse rates are high. Systemic glucocorticoids should be reserved to patients unable to take budesonide. In glucocorticoid refractory disease, medications that have been tried include cholestyramine, bismuth salicylate, antibiotics, probiotics, aminosalicylates, immunomodulators, and anti-tumor necrosis factor-alpha inhibitors. More research is needed for the creation of a systematic stepwise approach for relapsing and refractory disease. Keywords: microscopic colitis, diarrhea, collagenous colitis, lymphocytic colitis, management, inflammatory colitis  
topic microscopic colitis
diarrhea
collagenous colitis
lymphocytic colitis
management
url https://www.dovepress.com/management-of-microscopic-colitis-challenges-and-solutions-peer-reviewed-article-CEG
work_keys_str_mv AT shorj managementofmicroscopiccolitischallengesandsolutions
AT churrangog managementofmicroscopiccolitischallengesandsolutions
AT hosseinin managementofmicroscopiccolitischallengesandsolutions
AT marshallc managementofmicroscopiccolitischallengesandsolutions
_version_ 1724841335206182912